VistaGen Announces Positive Preclinical Data Supporting AV-101’s Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson’s Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine
Significant reduction of levodopa-induced dyskinesia by AV-101 observed in "gold standard" MPTP non-human primate model of Parkinson's disease, while maintaining...